Stock TVTX TRAVERE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
6.16 USD +2.67% Intraday chart for Travere Therapeutics, Inc. +13.03% -31.48%
04-24 EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment MT
04-24 Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy
Travere drug for rare kidney condition recommended for EU approval
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Mixed Premarket Friday
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Travere Therapeutics Expects $40 Million in Q4 Net Product Sales
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
Travere Therapeutics, Inc. Announces Program Updates and Anticipated 2024 Milestones
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Sector Update: Health Care
Travere Therapeutics Says Pre-NDA Meeting With FDA for IgA Nephropathy Drug 'Successful'; Plans 20% Job Cut; Shares Jump Pre-Bell
Travere Therapeutics, Inc. Completes Successful Pre-NDA Meeting for FILSPARI in IgAN
Travere Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVTX Stock
  4. News Travere Therapeutics, Inc.
  5. Other languages